Thomas Ebensen

Braunschweig, NI, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Mucosal vaccination with outer membrane vesicles derived from Bordetella pertussis reduces nasal bacterial colonization after experimental infection.

Mucosal vaccination with outer membrane vesicles derived from Bordetella pertussis reduces nasal bacterial colonization after experimental infection.

Journal: Frontiers in immunology

Published: October 05, 2024

HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.

HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.

Journal: Euroasian journal of hepato-gastroenterology

Published: September 28, 2024

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses.

Journal: Journal of virology

Published: August 22, 2024

New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.

New Generation Self-Replicating RNA Vaccines Derived from Pestivirus Genome.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 30, 2024

Diversification of a Novel α-Galactosyl Ceramide Hotspot Boosts the Adjuvant Properties in Parenteral and Mucosal Vaccines.

Diversification of a Novel α-Galactosyl Ceramide Hotspot Boosts the Adjuvant Properties in Parenteral and Mucosal Vaccines.

Journal: Angewandte Chemie (International ed. in English)

Published: July 31, 2023

Immune responses following neonatal vaccination with conserved F4 fragment of VtaA proteins from virulent Glaesserella parasuis adjuvanted with CAF®01 or CDA.

Immune responses following neonatal vaccination with conserved F4 fragment of VtaA proteins from virulent Glaesserella parasuis adjuvanted with CAF®01 or CDA.

Journal: Vaccine: X

Published: March 08, 2023

Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.

Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.

Journal: Pharmaceutics

Published: December 09, 2022

Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity.

Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity.

Journal: Pharmaceutics

Published: November 29, 2022

Correction: Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection.

Correction: Itaconate and derivatives reduce interferon responses and inflammation in influenza A virus infection.

Journal: PLoS pathogens

Published: November 29, 2022

IFN-α/β Signaling Is Required for CDG-Mediated CTL Generation and B Lymphocyte Activation.

IFN-α/β Signaling Is Required for CDG-Mediated CTL Generation and B Lymphocyte Activation.

Journal: Pharmaceutics

Published: November 23, 2022

Coatsome-replicon vehicles: Self-replicating RNA vaccines against infectious diseases.

Coatsome-replicon vehicles: Self-replicating RNA vaccines against infectious diseases.

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: October 10, 2022

MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.

MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination.

Journal: Cellular & molecular immunology

Published: May 27, 2021

Showing 1-12 of 58

Last Updated: 09/26/2026